Glycomimetics Inc., of Rockville, Md., said the first of two patient cohorts in its phase II acute myeloid leukemia (AML) trial of GMI-1271 completed enrollment. The cohort comprises 25 patients, 60 and older, with newly diagnosed AML. It's designed to evaluate the potential of GMI-1271, an E-selectin antagonist drug candidate, in combination with chemotherapy, as a treatment for patients with both newly diagnosed and relapsed/refractory AML. Enrollment in the study's second arm is expected to complete in the middle of this year. The two arms combined will enroll a total of about 90 patients. Read More
Replicel Life Sciences Inc., of Vancouver, British Columbia, said it has retained the Freemind Group to assist in securing nondilutive capital to support research, clinical development, and/or manufacturing priorities to accelerate value creation and the commercialization of its products. Read More
Replicel Life Sciences Inc., of Vancouver, British Columbia, has applied to the TSX Venture Exchange for an amendment to the exercise price of 148,226 non-transferable share purchase warrants expiring April 10 from $5 to $1.14 and 173,900 non-transferable share purchase warrants expiring on Nov. 20 from $4 to $1.14. Read More
LONDON – Newco Valo Therapeutics Ltd. has spun out of Helsinki University, Finland, with €3 million (US$3.2 million) of a first tranche of seed funding to commercialize next-generation peptide-coated oncolytic viruses that promote a specific antitumor immune activation. Read More
Pentamidine, an antiparasitic drug that is on the World Health Organization's (WHO) list of essential medicines and is used to treat conditions including leishmaniasis and pneumocystis pneumonia, sensitized gram-negative bacteria to antibiotics that are usually effective only for treating gram-positive bugs, including bacterial strains that were resistant to colistin. Read More
With enrollment about six months ahead of schedule, precision medicine specialist Dalcor Pharmaceuticals Inc. has randomized more than 1,000 patients of the expected 5,000 for the phase III dal-Gene trial, a cardiovascular outcomes (CVOT) study of dalcetrapib in patients with acute coronary syndrome (ACS) who have the AA genotype in the ADCY9 gene. Read More
Roche Holding AG plans to initiate a pair of new pivotal phase III studies testing the beta-amyloid-targeting monoclonal antibody gantenerumab in patients with prodromal to mild Alzheimer's disease (AD) in hopes that a higher dose of the drug might yield benefits that lower doses did not. Read More
